| ID | 1170 |
| Name of the vaccine | rF1V |
| Microbe | Bacteria |
| Disease name | Plague |
| Name of bacteria | Yersinia pestis |
| Type of vaccine | Recombinant |
| Nucleic acid content | Circular DNA |
| Age | 18 to 55 years |
| Description of the vaccine | Recombinant Plague vaccine. |
| Name of the manufacturer | DynPort Vaccine Company LLC, A GDIT Company |
| Name of the manufacturing country | United States |
| Year of manufacture | 2012 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dosage and two 3-dose schedules. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Protects from fatal pneumonic plague. |
| Export | NA |
| Approval | NA |
| Adjuvant | With or without Alhydrogel |
| Repurposing | NA |
| Side effects of vaccine | Transient edema and erythema at the injection site. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | Yes (enzootic from wild rodents and their fleas) |
| PubMed identifier | 23908395 |
| Clinical trial number | NCT01122784 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|